Clinical trial
A Study to Assess Capecitabine (Xeloda®) in Patients With Locally Advanced or…
NCT00077857 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00077857 |
|---|---|
| Title | A Study to Assess Capecitabine (Xeloda®) in Patients With Locally Advanced or Metastatic Breast Cancer |
| Official title | A Randomized, Open-label Study of the Effect of Different Dosing Regimens of Xeloda® in Combination With Taxotere® on Disease Progression in Patients With Locally Advanced and/or Metastatic Breast Cancer |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | capecitabine (Xeloda®), docetaxel (Taxotere®) |
| Enrollment | 470 |
| Start date | Jul 1, 2003 |
| Primary completion | Mar 1, 2010 |
| Completion | Mar 1, 2010 |
| First posted | Feb 16, 2004 |
| Last update posted | May 10, 2013 |
| Countries | Bosnia and Herzegovina, China, Czechia, India, Poland, Russia, South Africa, Thailand, United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: